Amphastar Pharmaceuticals (AMPH) Receives Analyst Rating

Amphastar Pharmaceuticals (AMPH) has an average broker rating of 1.2, which is interpreted as a Strong Buy, as rated by 5 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Ranking by Zacks Investment Research for Coach Inc is 1, which is also a Strong Buy.

Amphastar Pharmaceuticals (AMPH) : 4 Wall Street analysts covering Amphastar Pharmaceuticals (AMPH) believe that the average level the stock could reach for the short term is $21. The maximum price target given is $23 and the minimum target for short term is around $19, hence the standard deviation is calculated at $1.83.


Also, Brokerage firm Jefferies maintains its rating on Amphastar Pharmaceuticals (NASDAQ:AMPH). As per the latest information, the brokerage house raises the price target to $19 per share from a prior target of $16. The shares have been rated Buy. The rating by the firm was issued on August 9, 2016.

Amphastar Pharmaceuticals (NASDAQ:AMPH): After opening at $18.31, the stock dipped to an intraday low of $18.28 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $18.69 and the buying power remained strong till the end. The stock closed at $18.665 for the day, a gain of 2.39% for the day session. The total traded volume was 455,508. The stocks close on the previous trading day was $18.23.

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically-challenging generic and injectable and inhalation products. The Company has two operational segments: finished pharmaceutical products and active pharmaceutical ingredients (API products). The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, naloxone, lidocaine jelly, as well as, various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 17 products and is developing a portfolio of approximately 13 generic and eight injectable and inhalation product candidates. In addition to its marketed products, it has a pipeline of approximately 21 generic and product candidates in various stages of development which target a variety of indications.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.